Citations should be made in the following way: Authors. Title. Eur Respir J 2015; 46: Suppl. 59, abstract number.
Citations should be made in the following way: Authors. Title. Eur Respir J 2015; 46: Suppl. 59, abstract number.
Non-small cell lung cancer (NSCLC): sequence, timing, and modality of multi-line therapies
Symposium Chairs: Nicolas Schönfeld (Berlin, Germany), Fernando Gamarra (Straubing, Germany)
Aims: Most lung cancer patients must undergo a second-line therapy. A substantial number will also undergo third, fourth, and further lines of therapy. While first-line therapies are well supported by scientific evidence, there are far fewer well-designed clinical trials that support the use of second-line and especially further line therapies. Moreover, there are little data available that helps the clinician to reliably select the sequence, timing, and modality of multi-line therapies. This symposium focuses on various aspects of multi-line therapies in clinical practice in terms of treatment response, symptom control, and quality of life.
Target audience: Researchers who are interested in medical oncology, clinical scientists, clinicians with an interest in the molecular basis of thoracic malignancies, and all specialists involved in the diagnostic and therapeutic management of lung cancer.